Merck’s interim results from a dose-ranging Phase II trial of new integrase inhibitor MK-0518 showed that the oral drug — at all three doses studied (200 mg, 400 mg, and 600 mg orally twice daily) in combination with optimized background therapy (OBT) –had greater anti-retroviral activity than placebo with OBT. Study results also showed that MK-0518 in combination with OBT was generally well tolerated in these patients with advanced HIV infection who were failing anti-retrovira...